A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

Author： Sawka C.A.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.44, Iss.3, 1997-07, pp. : 211-215

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19

By Liu Jianhua   Tu Dongsheng   Dancey Janet   Reyno Leonard   Pritchard Kathleen I.   Pater Joseph   Seymour Lesley K  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 263-271

Springer Publishing Company

Access to resources Recommend Favorite

An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer

By Crump M.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 201-210

Springer Publishing Company

Access to resources Recommend Favorite

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial

By O’Malley F.   Chia S.   Tu D.   Shepherd L.   Levine M.   Huntsman D.   Bramwell V.   Andrulis I.   Pritchard K.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 401-409

Springer Publishing Company

Access to resources Recommend Favorite

Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 133-134

Informa Healthcare

Access to resources Recommend Favorite

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide

By Johansson Harriet   Bonanni Bernardo   Gandini Sara   Guerrieri-Gonzaga Aliana   Cazzaniga Massimiliano   Serrano Davide   Macis Debora   Puccio Antonella   Sandri Maria   Gulisano Marcella   Formelli Franca   DeCensi Andrea  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 569-578

Springer Publishing Company

Access to resources Recommend Favorite